133 related articles for article (PubMed ID: 37595597)
1. Clinical Characteristics and Outcomes of a High-grade Endometrial Cancer Cohort Treated at Instituto Nacional de Câncer, Brazil.
Paulino E; Melo AC
Rev Bras Ginecol Obstet; 2023 Jul; 45(7):e401-e408. PubMed ID: 37595597
[TBL] [Abstract][Full Text] [Related]
2. Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes.
Smart A; Buscariollo D; Alban G; Buzurovic I; Cheng T; Pretz J; Krechmer B; King M; Lee L
Int J Gynecol Cancer; 2020 Dec; 30(12):1908-1914. PubMed ID: 32655012
[TBL] [Abstract][Full Text] [Related]
3. Does the FIGO 2009 endometrial cancer staging system more accurately correlate with clinical outcome in different histologies? Revised staging, endometrial cancer, histology.
Page BR; Pappas L; Cooke EW; Gaffney DK
Int J Gynecol Cancer; 2012 May; 22(4):593-8. PubMed ID: 22343970
[TBL] [Abstract][Full Text] [Related]
4. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
[TBL] [Abstract][Full Text] [Related]
5. Comparative Survival Outcomes of Uterine Papillary Serous Carcinoma, Clear Cell Carcinoma, Grade 3 Endometrioid Adenocarcinoma, and Carcinosarcoma of Endometrial Cancer in Rajavithi Hospital.
Prueksaritanond N; Chantape W
J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S75-83. PubMed ID: 27266220
[TBL] [Abstract][Full Text] [Related]
6. Disparities in adjuvant treatment of high-grade endometrial cancer in the Medicare population.
Corey L; Cote ML; Ruterbusch JJ; Vezina A; Winer I
Am J Obstet Gynecol; 2022 Apr; 226(4):541.e1-541.e13. PubMed ID: 34736911
[TBL] [Abstract][Full Text] [Related]
7. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
[TBL] [Abstract][Full Text] [Related]
8. An Assessment of Prognostic Factors, Adjuvant Treatment, and Outcomes of Stage IA Polyp-Limited Versus Endometrium-Limited Type II Endometrial Carcinoma.
Liang LW; Perez AR; Cangemi NA; Zhou Q; Iasonos A; Abu-Rustum N; Alektiar KM; Makker V
Int J Gynecol Cancer; 2016 Mar; 26(3):497-504. PubMed ID: 26825840
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
Zhu J; Wen H; Bi R; Wu X
J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
[TBL] [Abstract][Full Text] [Related]
10. Impact of different adjuvant treatment approaches on survival in stage III endometrial cancer: A population-based study.
van Weelden WJ; Reijnen C; Eggink FA; Boll D; Ottevanger PB; van den Berg HA; van der Aa MA; Pijnenborg JMA
Eur J Cancer; 2020 Jul; 133():104-111. PubMed ID: 32454416
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of pretreatment thrombocytosis in endometrial cancer: an Israeli Gynecologic Oncology Group study.
Tal O; Eitan R; Gemer O; Helpman L; Vaknin Z; Leytes S; Lavie O; Ben-Arie A; Amit A; Namazov A; Ben Shahar I; Atlas I; Bruchim I; Levy T
Int J Gynecol Cancer; 2021 Nov; 31(11):1437-1442. PubMed ID: 34725243
[TBL] [Abstract][Full Text] [Related]
12. Impact of adjuvant treatment on outcome in high-risk early-stage endometrial cancer: a retrospective three-center study.
Helpman L; Perri T; Lavee N; Hag-Yahia N; Chariski HA; Kalfon S; Derazne E; Beiner ME; Kadan Y; Fishman A; Korach J; Covens A; Gien L
Int J Gynecol Cancer; 2019 Jan; 29(1):133-139. PubMed ID: 30640695
[TBL] [Abstract][Full Text] [Related]
13. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy.
Hochreiter A; Kelly JR; Young MR; Litkouhi B; Black JD; Stromberger C; Higgins S; Schwartz PE; Damast S
Int J Gynecol Cancer; 2020 Jan; 30(1):48-55. PubMed ID: 31722964
[TBL] [Abstract][Full Text] [Related]
14. Malignant peritoneal cytology and increased mortality risk in stage I non-endometrioid endometrial cancer.
Matsuo K; Nusbaum DJ; Matsuzaki S; Chang EJ; Roman LD; Wright JD; Harter P; Klar M
Gynecol Oncol; 2020 Oct; 159(1):43-51. PubMed ID: 32690393
[TBL] [Abstract][Full Text] [Related]
15. Hysteroscopic Morcellation in Endometrial Cancer Diagnosis: Increased Risk?
Kelly RA; Contos GT; Walker CA; Ayoola-Adeola M; Kim S; Winer IS
J Minim Invasive Gynecol; 2021 Sep; 28(9):1625-1632. PubMed ID: 33571678
[TBL] [Abstract][Full Text] [Related]
16. Uterine Papillary Serous Carcinoma: A Single-Institution Review of 62 Cases.
Black C; Feng A; Bittinger S; Quinn M; Neesham D; McNally O
Int J Gynecol Cancer; 2016 Jan; 26(1):133-40. PubMed ID: 26588230
[TBL] [Abstract][Full Text] [Related]
17. Survival Differences Among Uterine Papillary Serous, Clear Cell and Grade 3 Endometrioid Adenocarcinoma Endometrial Cancers: A National Cancer Database Analysis.
McGunigal M; Liu J; Kalir T; Chadha M; Gupta V
Int J Gynecol Cancer; 2017 Jan; 27(1):85-92. PubMed ID: 27759595
[TBL] [Abstract][Full Text] [Related]
18. Comparison of survival outcomes and effects of therapy between subtypes of high-grade endometrial cancer - a population-based study.
Scharl S; Gerken M; Sprötge T; Kronberger K; Scharl A; Ignatov A; Ortmann O; Kölbl O; Klinkhammer-Schalke M; Papathemelis T
Acta Oncol; 2021 Jul; 60(7):897-903. PubMed ID: 33905297
[TBL] [Abstract][Full Text] [Related]
19. The nature of early-stage endometrial cancer recurrence-A national cohort study.
Jeppesen MM; Jensen PT; Gilså Hansen D; Iachina M; Mogensen O
Eur J Cancer; 2016 Dec; 69():51-60. PubMed ID: 27816832
[TBL] [Abstract][Full Text] [Related]
20. The role of adjuvant chemotherapy in surgical stages I-II serous and clear cell carcinomas and carcinosarcoma of the endometrium: a collaborative study.
Vandenput I; Trovik J; Vergote I; Moerman P; Leunen K; Berteloot P; Neven P; Salvesen H; Amant F
Int J Gynecol Cancer; 2011 Feb; 21(2):332-6. PubMed ID: 21270614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
